Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies

Medical Physics

Volumn 38, Issue 8, 2011, Pages 4824-4845

  Dezarn, William A ^a   Cessna, Jeffery T ^b   Dewerd, Larry A ^c   Feng, Wenzheng ^d   Gates, Vanessa L ^e   Halama, James ^f   Kennedy, Andrew S ^g   Nag, Subir ^h   Sarfaraz, Mehrdad ⁱ   Sehgal, Varun ^j   Selwyn, Reed ^k   Stabin, Michael G ^l   Thomadsen, Bruce R ^c   Williams, Lawrence E ^m   Salem, Riad ^e  

^a Medical Radiation Physics Inc   (United States)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g Wake Radiology Oncology Services   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ GREATER BALTIMORE MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

brachytherapy; dosimetry; imaging; liver; microsphere; radioembolization; yttrium

Indexed keywords

DOSIMETRY; IMAGING TECHNIQUES; LIVER; ONCOLOGY; QUALITY ASSURANCE; RADIOACTIVE MATERIALS; RADIOTHERAPY; YTTRIUM;

BRACHYTHERAPY; FUTURE IMPROVEMENTS; IMAGING MODALITY; IMPLEMENTATION STRATEGIES; LIVER MALIGNANCIES; PROVIDE GUIDANCES; QUALITY ASSURANCE PROCEDURES; RADIOEMBOLIZATION;

MICROSPHERES;

EID: 79961045223     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3608909     Document Type: Article

References (64)

1. C. Breedis and G. Young, The blood supply of neoplasms in the liver., Am. J. Pathol. 30, 969-984 (1954).
2. J. Ingold, G. Reed, and H. Kaplan, Radiation hepatitis., Am. J. Roentgenol. 93, 200-208 (1965).
3. C. C. Pan, B. D. Kavanagh, L. A. Dawson, X. A. Li, S. K. Das, M. Miften, and R. K. T. Haken, Radiation-associated liver injury., Int. J. Radiat. Oncol. Biol. Phys. 76, S94-S100 (2010). 10.1016/j.ijrobp.2009.06.092
4. L. A. Dawson, C. J. McGinn, D. Normolle, R. K. Ten Haken, S. Walker, W. Ensminger, and T. S. Lawrence, Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies., J. Clin. Oncol. 18, 2210-2218 (2000). (Pubitemid 30350212)
5. A. Kennedy, S. Nag, R. Salem, R. Murthy, A. J. McEwan, C. Nutting, A. Benson, 3rd, J. Espat, J. I. Bilbao, R. A. Sharma, J. P. Thomas, and D. Coldwell, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium., Int. J. Radiat. Oncol. Biol. Phys. 68, 13-23 (2007). 10.1016/j.ijrobp.2006.11.060 (Pubitemid 46589861)
6. 90Y microspheres in man: Review of four explanted whole livers., Int. J. Radiat. Oncol. Biol. Phys. 60, 1552-1563 (2004). 10.1016/j.ijrobp.2004.09.004 (Pubitemid 39601873)
7. 2 glasses for the in vivo delivery of beta radiation., J. Biomed. Mater. Res. 27, 1301-1308 (1993). 10.1002/jbm.v27:10 (Pubitemid 23289652)
8. B. Carr, Hepatic arterial yttrium labeled glass microspheres TheraSphere as treatment for unresectable HCC in 36 patients., Proceedings of ASCO Journal of Clinical Oncology, Orlando FL, 2002.
9. B. Gray, G. Van Hazel, M. Hope, M. Burton, P. Moroz, J. Anderson, and V. Gebski, Randomised trial of SIR-Spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer., Ann. Oncol. 12, 1711-1720 (2001). 10.1023/A:1013569329846 (Pubitemid 34105661)
10. 90Y-microspheres: Early results in 148 patients., Am. J. Clin. Oncol. 31, 271-279 (2008). 10.1097/COC.0b013e31815e4557
11. 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience., Int. J. Radiat. Oncol. Biol. Phys. 65, 412-425 (2006). 10.1016/j.ijrobp.2005.12.051
12. 90Y-microspheres., J. Nucl. Med. 41, 1673-1681 (2000).
13. C. Couinaud, Le Foie: tudes anatomiques et chirurgicales The Liver: Anatomical and Surgical Studies Masson, Paris, France, 1957.
14. 90yttrium- microspheres for inoperable hepatic tumors., Int. J. Radiat. Oncol. Biol. Phys. 33, 919-924 (1995). 10.1016/0360-3016(95)00039-3
15. 99mTc-MAA for lung scanning., J. Nucl. Med. 14, 702-705 (1973).
16. 99mTc macroaggregated albumin., Br. J. Radiol. 70, 823-828 (1997). (Pubitemid 27373117)
17. 90Y microspheres: Angiographic and technical considerations., Cardiovasc. Intervent. Radiol. 4, 571-592 (2007). (Pubitemid 350092259)
18. J. S. Welsh, A. S. Kennedy, and B. Thomadsen, Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma., Int. J. Radiat. Oncol. Biol. Phys. 66, S62-S73 (2006).
19. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm? num=p990065. Last accessed March 2011.
20. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm? num=H980006. Last accessed March 2011. This is the original indication. Please see manufacturer for complete current indication as given in the report.
21. http://www.nucleide.org/DDEP-WG/Nuclides/Y-90-tables.pdf. Last accessed March 2011.
22. Dosimetry of beta rays and low-energy photons for brachytherapy with sealed sources (Report 72), J. ICRU 4, (2004).
23. D. J. Simpkin and T. R. Mackie, EGS4 Monte Carlo determination of the beta dose kernel in water., Med. Phys. 17, 179-186 (1990). 10.1118/1.596565 (Pubitemid 20140135)
24. 90 Sr., Appl. Radiat. Isot. 65, 318-327 (2007). 10.1016/j.apradiso.2006.08.009 (Pubitemid 44960818)
25. J. A. Siegel, S. R. Thomas, J. B. Stubbs, M. G. Stabin, M. T. Hays, K. F. Koral, J. S. Robertson, R. W. Howell, B. W. Wessels, D. R. Fisher, D. A. Weber, and A. B. Brill, MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates., J. Nucl. Med. 40, 37S-61S (1999). (Pubitemid 29077103)
26. A. Liu, L. E. Williams, and A. A. Raubitschek, A CT assisted method for absolute quantitation of internal radioactivity., Med. Phys. 23, 1919-1928 (1996). 10.1118/1.597755 (Pubitemid 26394094)
27. R. Loevinger, T. Budinger, and E. Watson, MIRD Primer for Absorbed Dose Calculations, Revised Edition (Society of Nuclear Medicine, New York, 1991).
28. S. Ho, W. Y. Lau, T. W. Leung, M. Chan, P. J. Johnson, and A. K. Li, Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer., Eur. J. Nucl. Med. 24, 293-298 (1997). (Pubitemid 27165858)
29. S. Ho, W. Y. Lau, T. W. Leung, M. Chan, Y. K. Ngar, P. J. Johnson, and A. K. Li, Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours., Eur. J. Nucl. Med. 23, 947-952 (1996). 10.1007/BF01084369 (Pubitemid 26278795)
30. M. G. Stabin, Update: The case for patient-specific dosimetry in radionuclide therapy., Cancer Biother. Radiopharm. 23, 273-284 (2008). 10.1089/cbr.2007.0445 (Pubitemid 351931455)
31. K. S. Kolbert, G. Sgouros, A. M. Scott, J. E. Bronstein, R. A. Malane, J. Zhang, H. Kalaigian, S. McNamara, L. Schwartz, and S. M. Larson, Implementation and evaluation of patient-specific three-dimensional internal dosimetry., J. Nucl. Med. 38, 301-308 (1997). (Pubitemid 27061616)
32. 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation., J. Nucl. Med. 46, 840-849 (2005).
33. A. Liu, L. E. Williams, G. Lopatin, D. M. Yamauchi, J. Y. C. Wong, and A. A. Raubitschek, A radionuclide therapy treatment planning and dose estimation system., J. Nucl. Med. 40, 1151-1153 (1999). (Pubitemid 29315507)
34. 131I SPECT quantification, registration and patient-specific dosimetry., Cancer Biother. Radiopharm. 18, 61-69 (2003). 10.1089/108497803321269331 (Pubitemid 36307467)
35. I. Clairand, M. Ricard, J. Gouriou, M. Di Paola, and B. Aubert, DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry., J. Nucl. Med. 40, 1517-1523 (1999). (Pubitemid 29428936)
36. J. Lehmann, C. H. Siantar, D. E. Wessol, C. A. Wemple, D. Nigg, J. Cogliati, T. Daly, M.-A. Descalle, T. Flickinger, D. Pletcher, and G. DeNardo, Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system., Phys. Med. Biol. 50, 947-958 (2005). 10.1088/0031-9155/50/5/017 (Pubitemid 40477315)
37. SN methods on three-dimensional unstructured grids., Nucl. Sci. Eng. 138, 256-268 (2001). (Pubitemid 32576332)
38. J. Mikell, O. Vassiliev, W. Erwin, T. Wareing, and F. Mourtada, Comparing a grid-based Boltzmann solver with Monte Carlo simulation for voxel-based therapeutic radionuclide dose calculations., Med. Phys. 36, 2772 (2009). 10.1118/1.3182516
39. A. K. Erdi, E. D. Yorke, M. H. Loew, Y. E. Erdi, M. Sarfaraz, and B. W. Wessels, Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy., Med. Phys. 25, 2226-2233 (1998). 10.1118/1.598422 (Pubitemid 28530115)
40. http://www.doseinfo-radar.com/RADARServices.html. Last accessed March 2011.
41. 2O., Med. Phys. 19, 105-114 (1992). 10.1118/1.596884
42. W. E. Bolch, L. G. Bouchet, J. S. Robertson, B. W. Wessels, J. A. Siegel, R. W. Howell, A. K. Erdi, B. Aydogan, S. Costes, E. E. Watson, A. B. Brill, N. D. Charkes, D. R. Fisher, M. T. Hays, and S. R. Thomas, MIRD pamphlet no. 17: The dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee., J. Nucl. Med. 40, 11-S36S (1999).
43. M. Sarfaraz, A. S. Kennedy, M. A. Lodge, X. A. Li, X. Wu, and C. X. Yu, Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma., Med. Phys. 31, 2449-2453 (2004). 10.1118/1.1781332 (Pubitemid 39287858)
44. G. L. DeNardo, D. J. Macey, S. J. DeNardo, C. G. Zhang, and T. R. Custer, Quantitative SPECT of uptake of monoclonal antibodies., Semin. Nucl. Med. 19, 22-32 (1989). 10.1016/S0001-2998(89)80033-9
45. 131I- Tositumomab therapy of previously untreated lymphoma patients., J. Nucl. Med. 44, 457-464 (2003). (Pubitemid 39586025)
46. 3H-standard efficiency tracing., J. Res. Natl. Inst. Stand. Technol. 102, 455-477 (1997). (Pubitemid 127665632)
47. 90Y., Appl. Radiat. Isot. 60, 741-749 (2004). 10.1016/j.apradiso.2003.12.009 (Pubitemid 38479512)
48. B. E. Zimmerman, R. Colle, and J. T. Cessna, Construction and implementation of the NIST triple-to-double coincidence ratio (TDCR) spectrometer., Appl. Radiat. Isot. 60, 433-438 (2004). 10.1016/j.apradiso.2003. 11.055 (Pubitemid 38264130)
49. B. E. Zimmerman and G. Ratel, Report of the CIPM key comparison CCRI(II)-K2.Y-90., Metrologia 42, 06001 (2005). 10.1088/0026-1394/42/1A/06001 (Pubitemid 41832814)
50. 90Y microspheres., Appl. Radiat. Isot. 63, 193-199 (2005). 10.1016/j.apradiso.2005. 02.002 (Pubitemid 40807142)
51. 90Y-labeled SIR-Spheres using a nondestructive spectroscopic assay., Med. Phys. 35, 1278-1279 (2008). 10.1118/1.2889621 (Pubitemid 351457493)
52. B. M. Coursey, J. M. Calhoun, and J. T. Cessna, Radioassays of yttrium-90 used in nuclear medicine., Nucl. Med. Biol. 20, 693-699 (1993). 10.1016/0969-8051(93)90040-2 (Pubitemid 23175374)
53. 90Y-ibritumomab tiuxetan., J. Nucl. Med. 45, 450-454 (2004). (Pubitemid 47618619)
54. 90Y using commercial radionuclide calibrators., Appl. Radiat. Isot. 60, 511-517 (2004). 10.1016/j.apradiso.2003.11.068 (Pubitemid 38264143)
55. 90Y activities compared to reference standard., Med. Phys. 34, 2489 (2007). 10.1118/1.2761105
56. 90Y microsphere activity measurements for liver brachytherapy., Med. Phys. 34, 1896-1900 (2007). 10.1118/1.2731034 (Pubitemid 47055722)
57. http://www.nrc.gov/materials/miau/med-use-toolkit.html. Last accessed March 2011. Follow links given under heading Other Guidance'.
58. 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part1: Technical and methodologic considerations., J. Vasc. Interv. Radiol. 17, 1251-1278 (2006). 10.1097/01.RVI.0000233785.75257. 9A (Pubitemid 44259009)
59. S. Nag, R. Dobelbower, G. Glasgow, G. Gustafson, N. Syed, B. Thomadsen, and J. F. Williamson, Inter-society standards for the performance of brachytherapy: A joint report from ABS, ACMP and ACRO., Crit. Rev. Oncol./Hematol. 48, 1-17 (2003). 10.1016/S1040-8428(03)00026-X (Pubitemid 37324687)
60. IAEA, Quality assurance for radioactivity measurement in nuclear medicine., International Atomic Energy Agency Technical Report Series No. 454 (2006).
61. http://acr.org/SecondaryMainMenuCategories/quality-safety/guidelines/toc. aspx. Last accessed March 2011.
62. http://www.aapm.org/pubs/reports. Last accessed March 2011.
63. W. A. Dezarn, Quality assurance issues for therapeutic application of radioactive microspheres., Int. J. Radiat. Oncol. Biol. Phys. 71, S147-S151 (2008). 10.1016/j.ijrobp.2007.05.094
64. B. R. Thomadsen, H. T. Heaton II, S. K. Jani, J. P. Masten, M. E. Napolitano, Z. Ouhib, C. S. Reft, M. J. Rivard, T. T. Robin, M. Subramanian, and O. H. Suleiman, Off-label use of medical products in radiation therapy: Summary of the report of AAPM task group no. 121., Med. Phys. 37, 2300-2311 (2010). 10.1118/1.3392286